Lisa Phuong, DO
Hematology & Oncology · Norwalk, CTNPI 1265826234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,064, 2.9 times the $371 reported in 2021.
Across 159 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$365
- Novartis$297
- Bristol Myers Squibb$231
- Gilead$202
- Genentech USA, Inc.$198
- Amgen$164
- plus $2K from 34 others
Across 11 payments — averaging $19,311 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$197K
- Pfizer$10K
- Genentech, Inc.$6K
What the payments were for
- Food & beverage$3,40893%
- Education$2617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $365 |
| Novartis | 13 | $297 |
| Bristol Myers Squibb | 10 | $231 |
| Gilead | 8 | $202 |
| Genentech USA, Inc. | 9 | $198 |
| Amgen | 6 | $164 |
| Incyte Corporation | 9 | $162 |
| Eisai Inc. | 7 | $144 |
| Regeneron Healthcare Solutions, Inc. | 6 | $143 |
| Seagen Inc. | 3 | $140 |
| Rigel Pharmaceuticals, Inc. | 5 | $132 |
| Johnson & Johnson | 5 | $114 |
| E.r. Squibb & Sons, L.L.C. | 4 | $93 |
| AbbVie | 1 | $83 |
| Sanofi | 4 | $81 |
| Bayer | 4 | $78 |
| EMD Serono, Inc. | 3 | $77 |
| Mirati Therapeutics, Inc. | 3 | $73 |
| ADC Therapeutics America, Inc. | 3 | $71 |
| Pfizer | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Astellas Pharma US Inc | 3 | $63 |
| GSK | 2 | $54 |
| Exelixis Inc. | 3 | $53 |
| Array Biopharma Inc | 2 | $53 |
| Stemline Therapeutics Inc. | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Lilly USA, LLC | 2 | $44 |
| Sobi, Inc | 2 | $43 |
| Merck | 2 | $40 |
| Coherus Oncology, Inc. | 2 | $39 |
| AVEO Pharmaceuticals, Inc. | 2 | $31 |
| Geron Corporation | 1 | $28 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
How this compares
$3,669 in reported general payments places this provider in the 60th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 13 | $241,140 |
| EliquisApixaban | 13 | $14,175 |
| Anastrozole | 174 | $2,668 |
| Tamoxifen Citrate | 78 | $1,984 |
| Exemestane | 22 | $1,785 |
| Letrozole | 31 | $548 |
| Gabapentin | 24 | $145 |
| Hydroxyurea | 15 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $65 | $255,31526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Norwalk
- Richard ZelkowitzNorwalk$54K
- Richard FrankNorwalk$5K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.